FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

/ashington, D.C. 20549

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

							. 50(1	., 0. 1110			ompany 7 tot	0. 2040								
Name and Address of Reporting Person* Aliski William						2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE]									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC.					3. Date of Earliest Transaction (Month/Day/Year) 05/18/2020									Officer (give title below)				Other (specification)		
60 LEVERONI COURT					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street) NOVATO CA 94949													Line) X		iled by Mo	•	orting Perso n One Repo			
(City) (State) (Zip)																				
		Tab	le I - No	on-Deriv	ative	Sec	urit	ies Ac	quired	l, Di	sposed o	of, or Be	nefic	ially	Owned	k				
1. Title of Security (Instr. 3) 2. Transacting Date (Month/Day)					Exe) if ar	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquir Disposed Of (D) (In:				Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 05/18/20					2020				М		7,500	A	\$40).37	55	,424		D		
Common Stock 05/18/2				2020	020			S		7,500	D	\$74.	74.65 ⁽¹⁾ 47,9		924 ⁽²⁾		D			
Common Stock														90	,350			By trust ⁽³⁾		
Common Stock														9,	686			By trust ⁽⁴⁾		
Common Stock															18	,000			By trust ⁽⁴⁾	
		7	able II								osed of converti				wned			,		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr 8)		on of		6. Date E Expiration (Month/I	on Dat		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		S (I	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	is illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	V (A) (D)		Date Exercisa		Expiration Date	Title	Amou or Numb of Share	er						
Stock Option (Right to	\$40.37	05/18/2020			M			7,500	(5)		07/10/2024	Common Stock	7,50	0	\$0.00	0		D		

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$74.62 to \$74.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- 3. These shares are held in a trust for the benefit of the Reporting Person's spouse and children. The Reporting Person's spouse and nephew are trustees of the trust.
- 4. These shares are held in a grantor retained annuity trust. The Reporting Person is the trustee of the trusts.
- 5. The option was fully vested as of June 18, 2015.

Remarks:

/s/ Karah Parschauer, attorneyin-fact

05/20/2020

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.